Submissions from 2023
Variabilité interscoreurs entre 5 centres de sommeil comparé à une analyse cardio-actimétrique, Antoine Viola, Laurie Thiesse, Luc Staner, Gil Fuchs, Thomas Roth, Jean-Yves Schaffhausser, Jay Saoud, and Remy Luthringer
Submissions from 2022
Digital Cognitive Behavioral Therapy for Insomnia Promotes Resilience During the Coronavirus Disease 19 (COVID-19) Pandemic, Philip Cheng, M. Casement, David Kalmbach, Andrea Cuamatzi-Castelan, and Christopher Drake
COMPARATIVE EFFICACY OF DIGITAL CBT-I VERSUS STEPPED-CARE CBT-I TO PREVENT DEPRESSION, Philip Cheng, David Kalmbach, Zain Sultan, Cynthia Fellman-Couture, and Christopher Drake
P689. Improving Treatment Effectiveness in Marginalized Individuals: Facilitators and Barriers to Digital Cognitive Behavioral Therapy for Insomnia, Philip Cheng, Sara Santarossa, David A. Kalmbach, and Christopher L. Drake
Efficacy of Once-Nightly Sodium Oxybate (ONSXB; FT218) by Narcolepsy Type: Post-Hoc Analyses from the REST-ON Trial, Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J. Thorpy, Anne M. Morse, Asim Roy, David Seiden, Jordan Dubow, and Jennifer Gudeman
Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia, Christopher Drake, J. Yardley, K. Pinner, and M. Moline
Evaluation of Long-term Perception of Medication Effectiveness: Results from Subjects Receiving Lemborexant for up to 12 Months, Christopher Drake, J. Yardley, K. Pinner, C. Perdomo, and M. Moline
Positional therapy in a patient with refractory treatment-emergent central sleep apnea, Miriam Jaziri, William Palmer, and Maria Tovar
IMPROVING DETECTION OF OBSTRUCTIVE SLEEP APNEA IN PREGNANT WOMEN USING A SIX-POINT SCREENING TOOL, Miriam Jaziri, Nicolina Smith, Luisa Bazan, D'Angela Pitts, and David Kalmbach
Efficacy of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: Post-hoc Sensitivity Analyses From the REST-ON Trial, Clete Kushida, Thomas Roth, Michael Thorpy, David Seiden, Jordan Dubow, and Jennifer Gudeman
EFFICACY OF FT218, A ONCE-NIGHTLY SODIUM OXYBATE FORMULATION, IN PATIENTS WITH NARCOLEPSY: POST-HOC SENSITIVITY ANALYSES FROM THE REST-ON TRIAL, Clete Kushida, Thomas Roth, Michael Thorpy, David Seiden, Jordan Dubow, and Jennifer Gudeman
SLEEP ASSESSED BY ACTIGRAPHY DURING DISCONTINUATION OF CHRONIC HYPNOTIC USE, Vartika Parashar, Gail Koshorek, Thomas Roth, and Timothy Roehrs
Self-reported perceptions of medication effectiveness in subjects receiving lemborexant for up to 12 months, K. Pinner, Christopher Drake, J. Yardley, C. Perdomo, and M. Moline
SLEEP REACTIVITY PROSPECTIVELY PREDICTS DISTRESS REACTIONS TO THE COVID-19 PANDEMIC 3-4 YEARS LATER, Anthony Reffi, Philip Cheng, David Kalmbach, Zain Sultan, and Christopher Drake
The incidence of abnormal dreams and nightmares in adults with insomnia treated with lemborexant: results from two Phase 3 studies, Thomas Roth, J. Yardley, K. Pinner, D. Kumar, J Y. Cheng, and M. Moline
Lemborexant versus Zolpidem: An Assessment of Wake Bouts in Adults with Insomnia, Thomas Roth, G. Zammit, D. Kumar, E. Pappadopulos, and M. Moline
Severe multisystem inflammatory response to COVID-19 vaccination, Dania A. Shakaroun and John Buckley
Efficacy of Once-Nightly Sodium Oxybate (ON-SXB; FT218) Across Stimulant Use Subgroups: Post-hoc Analyses From the REST-ON Trial, Michael Thorpy, Yves Dauvilliers, Thomas Roth, Ann M. Morse, Asim Roy, Richard Bogan, David Seiden, Jordan Dubow, and Jennifer Gudeman
EFFICACY OF ONCE-NIGHTLY SODIUM OXYBATE (ON-SXB; FT218) ACROSS STIMULANT USE SUBGROUPS: POST-HOC ANALYSES FROM THE REST-ON TRIAL, Michael Thorpy, Yves Dauvilliers, Thomas Roth, Ann M. Morse, Asim Roy, Richard Bogan, David Seiden, Jordan Dubow, and Jennifer Gudeman
Efficacy of Once-nightly Sodium Oxybate (ON-SXB; FT218) for Excessive Daytime Sleepiness and Cataplexy: Post-hoc Number Needed to Treat and Effect Size Analyses From REST-ON, Michael Thorpy, Thomas Roth, Clete Kushida, David Seiden, Jordan Dubow, and Jennifer Gudeman
Comparison of the paroxetine's effect on the sleep parameters measurements extracted by polysomnography vs somno-art in depressed patients, A. Viola, L. Thiesse, L. Staner, G. Fuchs, D. Kirscher, Thomas Roth, J. Y. Schaffhauser, J. Saoud, and R. Luthringer
Impact of Lemborexant Versus Placebo and Zolpidem on REM Sleep Duration by Quarter-of-the-Night Intervals in Older Adults with Insomnia Disorder, G. Zammit, Thomas Roth, D. Kumar, C. Perdomo, and M. Moline
Submissions from 2021
1156 Social determinants of sleep in black pregnant women, D'Angela S. Pitts, Nicolina M. Smith, Mariam Ayyash, and Louise O'Brien
102 The efficacy of a pilot program for obstructive sleep apnea screening in pregnancy, Nicolina Smith, Matthew Floyd, Roopina Sangha, Philip Cheng, Angela Osborne, D'Angela S. Pitts, and Luisa Bazan
Submissions from 2020
Subject-reported perception of long-term effectiveness of lemborexant versus placebo in nonelderly and elderly subgroups, Christopher l. Drake, J Yardley, K Pinner, C Perdomo, and M Moline
Clot distribution in pulmonary embolism does not influence right ventricular recovery, Jennifer Hines, M Floyd, Reem Ismail, Phong Le, Gillian Grafton, Bryan A. Kelly, Sara Hegab, and Rana Awdish
Coupling Continuous Positive Airway Pressure (CPAP) and MR-guided Radiation Therapy, Evan Liang, Eric D. Morris, Jonathan Vono, Luisa Bazan, Mei Lu, Ankit Modh, and Carri K. Glide-Hurst
Submissions from 2019
Risk-taking and circadian misalignment in night shift workers, Philip Cheng, Andrea Cuamatzi-Castelan, and Christopher L. Drake
Efficacy of a stepped-care CBT-I approach for insomnia, Philip Cheng, Cynthia Fellman-Couture, R L. Atkinson, Christine V. Tonnu, Kenneth Moss, and Christopher L. Drake
Comparative efficacy of digital CBT-I versus stepped-care CBT-I to reduce comorbid depression, Philip Cheng, Cynthia Fellman-Couture, R L. Atkinson, Christine V. Tonnu, Meeta Singh, and Christopher L. Drake
Predicting circadian phase in night shift workers using actigraphy, Philip Cheng, O J. Walch, Andrea Cuamatzi-Castelan, and Christopher L. Drake
Insomnia in late pregnancy: Characterizing phenotypes and identifying associated factors, Andrea Cuamatzi-Castelan, David A. Kalmbach, R L. Atkinson, Roopina Sangha, Luisa Bazan, L M. O'Brien, L M. Swanson, Thomas Roth, and Christopher L. Drake
Changes in use of sleep aids following digital cognitive behavioral therapy for insomnia, Christopher L. Drake, Philip Cheng, Gabriel Tallent, R L. Atkinson, Andrea Cuamatzi-Castelan, and Luisa Bazan
Arousability of insomnia patients is not impacted by the orexin antagonist suvorexant (10 mg and 20 mg), Christopher l. Drake, Andrea Cuamatzi-Castelan, David A. Kalmbach, Philip Cheng, Thomas Roth, Meeta Singh, M K. Tran, Christine V. Tonnu, R L. Atkinson, and Cynthia Fellman-Couture
Online medical education improves knowledge of physiologic mechanisms of sleep among neurologists and primary care clinicians, T Finnegan, C F. Murray, S Hughes, and Thomas Roth
Insomniacs in late pregnancy are clinically depressed: Exploring the role of nocturnal rumination, David A. Kalmbach, Andrea Cuamatzi-Castelan, Christine V. Tonnu, Roopina Sangha, L M. O'Brien, L M. Swanson, Thomas Roth, and Christopher L. Drake
Are people with severe insomnia able to discontinue hypnotics after chronic use?, Gail Koshorek, Jelena Verkler, Dana Withrow, Thomas Roth, and Timothy Roehrs
Effects of suvorexant on sleep in fibromyalgia, Gail Koshorek, Jelena Verkler, Dana Withrow, Thomas Roth, and Timothy Roehrs
Idiopathic hypersomnia symptom diary (IHSD): development of a new patient reported outcome (PRO) measure, M C. Lam, A Dorenbaum, L Lien, Thomas Roth, and S D. Mathias
Treatment of obstructive sleep apnea with positive airway pressure to improve cognitive function in mild cognitive impairment, Beth McLellan, Virginia Skiba, Marina Novikova, Lonni R. Schultz, and Aarushi Suneja
Pharmacokinetics and dose proportionality of FT218, an investigational controlled release formulation of sodium oxybate for once nightly dosing, D Monteith, J Grassot, C Castellan, and Thomas Roth
Pharmacokinetics and formulation selection of FT218, an investigational controlledrelease sodium oxybate formulation designed for once nightly dosing, D Monteith, J Grassot, C Castellan, and Thomas Roth
Are reports of mental fog from patients with idiopathic hypersomnia mediated by objective measures of daytime sleepiness?, Thomas Roth, A Dorenbaum, M Jaros, and M Lam
Lemborexant treatment for insomnia in phase 3: Impact on disease severity, Thomas Roth, R Rosenberg, P Murphy, J Yardley, D Kumar, K Pinner, C Perdomo, and M Moline
The impact of lemborexant treatment on insomnia disease severity: results from a pooled analysis of two phase 3 studies, Thomas Roth, R Rosenberg, J Yardley, D Kumar, K Pinner, C Perdomo, and M Moline
Baseline characteristics of idiopathic hypersomnia subjects enrolled in a clinical trial (ARISE2), Thomas Roth, L Rosenthal, A Avidan, N Baio, A Dorenbaum, M Lam, and M Thorpy
Characteristics of subjects excluded form an idiopathic hypersomnia randomized clinical trial (ARISE2), Thomas Roth, L Rosenthal, A Dorenbaum, N Baio, M Lam, and A Avidan
The pharmacokinetics of once-nightly controlled- release Sodium Oxybate (FT218): overview of results from four phase 1 studies, M Thorpy, J Dubow, D Monteith, J Grassot, Thomas Roth, J Winkelman, and B Corser
Polysomnography in insomnia disorder, Jelena Verkler, Gail Koshorek, Thomas Roth, and Timothy Roehrs
Effects of suvorexant on pain sensitivity in fibromyalgia, Dana Withrow, Jelena Verkler, Gail Koshorek, Thomas Roth, and Timothy Roehrs
Submissions from 2018
Efficacy of Cognitive Behavioral Therapy for Insomnia on Post-Menopausal Quality of Life, J T. Arnedt, Philip Cheng, Cynthia Fellman-Couture, G Tallent, David A. Kalmbach, Meeta Singh, Thomas Roth, and Christopher L. Drake
Comparison of Idiopathic Interstitial Pneumonia and Connective Tissue Disease Related Interstitial Lung Disease by Physiologic and Functional Testing Parameters, S K. Avasarala, Sarah Gorgis, Mohammed Dabbagh, A Saeed, C Gondolfo, N Garza, Jeffrey H. Jennings, and Krishna Thavarajah
Digital Cognitive Behavioral Therapy for Insomnia Reduces Incident Depression at Oneyear Follow-Up, Philip Cheng, G Tallent, A Luik, Edward L. Peterson, K Tran, Brian Ahmedani, D Adler, Thomas Roth, and Christopher L. Drake
Applicaiton of Mathematical Modeling for Faster Circadian Tntrainment, Philip Cheng, O Walch, and Christopher L. Drake
Using mathematical modeling to predict circadian phase in night shift workers, Philip Cheng, O Walch, K Tran, Andrea Cuamatzi-Castelan, and Christopher L. Drake
Long-term Efficacy of the Sleep to Prevent Evolving Affective Disorders (SPREAD) Trial as an Internet-based Treatment for Insomnia, Andrea Cuamatzi-Castelan, Philip Cheng, Cynthia Fellman-Couture, G Tallent, K Tran, C A. Espie, Christine LM Joseph, Timothy Roehrs, and Christopher L. Drake
Efficacy of SM-1 in a Transient Insomnia Model, T Dahl, Thomas Roth, M Ahmad, and L Chen
The Pharmacokinetics and Pharmacodynamics of SM-1, T Dahl, Thomas Roth, M Scheinin, J Suopanki-Lalowski, M Valge, A Puhakka, H Mikola, Z Lovró, A Meierjohann, L Vuorilehto, and L Chen
Examining the Effects of Slow-Wave Activity Disruption on Waking EEG Theta Activity, J Goldschmied, Philip Cheng, R Armitage, and P Deldin
Management of Ehlers-Danlos Related OSA with Home Sleep Testing and Auto-CPAP, J Hogaboam, K Moss, and L Bazan
Inability to Discontinue Chronic Hypnotic Use, Gail Koshorek, D Withrow, Thomas Roth, and Timothy Roehrs
The Impact of Treating Insomnia upon Functional Health, Psychological Wellbeing and Sleep-Related Quality of Life: A Randomised Controlled Trial with Mediation Analysis, A Luik, R Emsley, S D. Kyle, C Gordon, Christopher L. Drake, A Marsden, and C A. Espie
Relationship Between Efficacy Endpoints and Measures of Functional Status and Health-Related Quality of Life (HRQoL) in Obstructive Sleep Apnea patients Treated for Excessive Sleepiness, S D. Mathias, R D. Crosby, Christopher L. Drake, M Bron, S Bujanover, D Menno, and K F. Villa
Stress-Related Sleep Reactivity Predicts Peri-Partum Insomnia, Psychopathology and Suicidality, L Palagini, U Moretto, M Novi, D Caruso, and Christopher L. Drake
Markers for Hypnotic Abuse Liability: Cortisol in Insomnia?, Timothy Roehrs, Gail Koshorek, D Withrow, and Thomas Roth
Effectiveness of Recruiting Type 1 Narcolepsy Patients via Internet Based Pre-Selection System, Thomas Roth, S O'Daly, M Fenton, S Dowd, N Cassidy, J Allen, D Monteith, and S Klassen
Treatment of Obstructive Sleep Apnea with Positive Airway Pressure in Mild Cognitive Impairment, Aarushi Suneja, Virginia Skiba, Marina Novikova, Lonni Schultz, and Beth McLellan
Impact of Behavioral Insomnia Treatments on Quality of Life in Post-menopausal Women, G Tallent, Philip Cheng, Cynthia Fellman-Couture, Christine V. Tonnu, K Moss, T Arnedt, and Christopher L. Drake
Impact of Behavioral Insomnia Treatment on Post-Menopausal Female Sexual Functioning, Christine V. Tonnu, Philip Cheng, David A. Kalmbach, Cynthia Fellman-Couture, G Tallent, J Arnedt, Meeta Singh, and Christopher L. Drake
Insomnia and Stress: Associations with Mental Resilience and Mood, J. C. Verster, L. Palagini, M. Mackus, A. J. Van De Loo, J. Garssen, and Thomas Roth
Self-Reported Sleep During Discontinuation of Chronic Hypnotic Use, D Withrow, Gail Koshorek, Thomas Roth, and Timothy Roehrs
Submissions from 2017
Clinical Profile of Suvorexant for the Treatment of Insomnia over 3 Months in Women and Men: Subgroup Analysis of Pooled Phase-3 Data, W J. Herring, K M. Connor, E Snyder, D B. Snavely, Y Zhang, J Hutzelmann, D Matzura-Wolfe, R M. Benca, A D. Krystal, J K. Walsh, C Lines, Thomas Roth, and D Michelson
